Clinical Trial Update: The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update investigating the use of MMC during PRK and its effect on postoperative topical steroid requirements across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Opacity

Drugs mentioned

• MMC (mitomycin-C)

Snippet

Sponsor: United States Naval Medical Center, San Diego | Conditions: Corneal Opacity | Phase 2, Phase 3 | Status: UNKNOWN